134 related articles for article (PubMed ID: 7527306)
21. Whole blood and plasma levels of FK 506 after liver transplantation: correlation with toxicity.
Bäckman L; Nicar M; Levy M; Distant D; Eisenstein C; Renard T; Goldstein R; Husberg B; Gonwa T; Klintmalm G
Transplant Proc; 1994 Jun; 26(3):1804. PubMed ID: 7518160
[No Abstract] [Full Text] [Related]
22. Evaluation of the Architect tacrolimus assay in kidney, liver, and heart transplant recipients.
Bazin C; Guinedor A; Barau C; Gozalo C; Grimbert P; Duvoux C; Furlan V; Massias L; Hulin A
J Pharm Biomed Anal; 2010 Dec; 53(4):997-1002. PubMed ID: 20674215
[TBL] [Abstract][Full Text] [Related]
23. Effects of hematocrit value on microparticle enzyme immunoassay of tacrolimus concentration in therapeutic drug monitoring.
Tomita T; Homma M; Yuzawa K; Ohkohchi N; Hori T; Kaneko M; Hasegawa Y; Kojima H; Nagasawa T; Kohda Y
Ther Drug Monit; 2005 Feb; 27(1):94-7. PubMed ID: 15665753
[TBL] [Abstract][Full Text] [Related]
24. Multicenter comparison of tacrolimus (FK 506) whole blood concentrations as measured by the Abbott IMX analyzer and enzyme immunoassay with methylene chloride extraction.
D'Ambrosio R; Girzaitis N; Jusko WJ
Ther Drug Monit; 1994 Jun; 16(3):287-92. PubMed ID: 7521979
[TBL] [Abstract][Full Text] [Related]
25. Cloned enzyme donor immunoassay tacrolimus assay compared with high-performance liquid chromatography-tandem mass spectrometry and microparticle enzyme immunoassay in liver and renal transplant recipients.
Westley IS; Taylor PJ; Salm P; Morris RG
Ther Drug Monit; 2007 Oct; 29(5):584-91. PubMed ID: 17898648
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic interpretation of FK 506 levels in blood and in plasma during a European randomised study in primary liver transplant patients. The FK 506 European Study Group.
Undre N; Möller A
Transpl Int; 1994; 7 Suppl 1():S15-21. PubMed ID: 11271189
[TBL] [Abstract][Full Text] [Related]
27. Increased rejection after liver transplantation in FK 506-treated patients is associated with viral hepatitis C disease.
Mueller AR; Platz KP; Bechstein WO; Blumhardt G; Lobeck H; Hop U; Neuhaus P
Transplant Proc; 1994 Dec; 26(6):3637-9. PubMed ID: 7527984
[No Abstract] [Full Text] [Related]
28. Relationship of whole-blood FK506 concentrations to rejection and toxicity in liver and kidney transplants.
Hedayat S; Kershner RP; Su G
J Biopharm Stat; 1996 Nov; 6(4):411-24. PubMed ID: 8969977
[TBL] [Abstract][Full Text] [Related]
29. Radioreceptor assay for quantifying FK-506 immunosuppressant in whole blood.
Murthy JN; Chen Y; Warty VS; Venkataramanan R; Donnelly JG; Zeevi A; Soldin SJ
Clin Chem; 1992 Jul; 38(7):1307-10. PubMed ID: 1377995
[TBL] [Abstract][Full Text] [Related]
30. Falsely elevated whole-blood tacrolimus concentrations in a kidney-transplant patient: potential hazards.
Rostaing L; Cointault O; Marquet P; Josse AG; Lavit M; Saint-Marcoux F; Kamar N
Transpl Int; 2010 Feb; 23(2):227-30. PubMed ID: 19761555
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the new EMIT tacrolimus assay in kidney and liver transplant recipients.
Akbas SH; Yavuz A; Tuncer M; Yurdakonar E; Akcit F; Gurkan A; Demirbas A; Gultekin M; Ersoy F; Akaydin M
Transplant Proc; 2004; 36(1):86-8. PubMed ID: 15013308
[TBL] [Abstract][Full Text] [Related]
32. Analysis of tacrolimus (FK 506) in relation to therapeutic drug monitoring.
Jusko WJ
Ther Drug Monit; 1995 Dec; 17(6):596-601. PubMed ID: 8588227
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of the new EMIT enzyme immunoassay for the determination of whole-blood tacrolimus concentrations in kidney, heart, and liver transplant recipients.
Hesse CJ; Baan CC; Balk AH; Metselaar HJ; Weimar W; van Gelder T
Transplant Proc; 2002 Nov; 34(7):2988-90. PubMed ID: 12431679
[No Abstract] [Full Text] [Related]
34. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation.
Kershner RP; Fitzsimmons WE
Transplantation; 1996 Oct; 62(7):920-6. PubMed ID: 8878385
[TBL] [Abstract][Full Text] [Related]
35. Immunosuppression switch in pediatric heart transplant recipients: cyclosporine to FK 506.
Swenson JM; Fricker FJ; Armitage JM
J Am Coll Cardiol; 1995 Apr; 25(5):1183-8. PubMed ID: 7534779
[TBL] [Abstract][Full Text] [Related]
36. Pharmacoepidemiology of tacrolimus in pediatric liver transplantation.
Riva N; Schaiquevich P; Cáceres Guido P; Halac E; Dip M; Imventarza O
Pediatr Transplant; 2017 Aug; 21(5):. PubMed ID: 28574195
[TBL] [Abstract][Full Text] [Related]
37. FK 506 in liver transplantation: correlation of whole blood levels with efficacy and toxicity. The US Multicenter FK 506 Dose Optimization.
Schwartz M; Holst B; Facklam D; Buell D
Transplant Proc; 1995 Feb; 27(1):1107. PubMed ID: 7533355
[No Abstract] [Full Text] [Related]
38. In vitro assessment of FK 506 immunosuppressive activity in transplant patients.
Zeevi A; Venkataramanan R; Warty V; Eiras G; Woan M; Abu-Elmagd K; Alessiani M; Jain A; Demetris AJ; Zerbe T
Transplant Proc; 1991 Dec; 23(6):2897-9. PubMed ID: 1721307
[No Abstract] [Full Text] [Related]
39. Is the affinity column-mediated immunoassay method suitable as an alternative to the microparticle enzyme immunoassay method as a blood tacrolimus assay?
Ju MK; Chang HK; Kim HJ; Huh KH; Ahn HJ; Kim MS; Kim SI; Kim YS
Transplant Proc; 2008 Dec; 40(10):3673-8. PubMed ID: 19100463
[TBL] [Abstract][Full Text] [Related]
40. Effect of the hematocrit and its correction on the relationship between blood tacrolimus concentrations obtained using the microparticle enzyme immunoassay (MEIA) and enzyme multiplied immunoassay technique (EMIT).
Bouzas L; Ortega FJ; Casado P; Arranz MI; Carcas A; Tutor JC
Clin Lab; 2007; 53(9-12):591-6. PubMed ID: 18257466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
